All stories44

A proposed $125 million business-losses settlement reached its approval hearing. Judgment remained reserved, with individual payments still unconfirmed.

The first authorisation became a rollout and a licensed vaccine. Later studies, heart-inflammation warnings and narrower approved use changed the story; another formula followed in 2026.

Liability findings survived appeal. The next step was individual claims assessment, with registration closing in March 2026—not a confirmed payment to every passenger.

The inquest findings arrived nearly five years later. A separate civil settlement followed.